Aquestive Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2017 to 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Aquestive Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2017 to 2024.
  • Aquestive Therapeutics, Inc. Operating Income (Loss) for the quarter ending December 31, 2024 was -$13.6M, a 247% decline year-over-year.
  • Aquestive Therapeutics, Inc. Operating Income (Loss) for the twelve months ending December 31, 2024 was -$30.8M, a 104% decline year-over-year.
  • Aquestive Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$30.8M, a 104% decline from 2023.
  • Aquestive Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$15.1M, a 64.1% increase from 2022.
  • Aquestive Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$42.1M, a 21.3% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$30.8M -$15.7M -104% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-05
2023 -$15.1M +$27M +64.1% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-05
2022 -$42.1M -$7.39M -21.3% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-05
2021 -$34.7M +$8.21M +19.2% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-31
2020 -$42.9M +$9.78M +18.6% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-08
2019 -$52.7M -$3.73M -7.63% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-09
2018 -$48.9M -$48.8M -43204% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-11
2017 -$113K Jan 1, 2017 Dec 31, 2017 10-K 2019-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.